Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

| Input:

Analysts expect strong second-quarter results driven by favorable exchange rates, but potential one-time labor expenses and early Rockville plant overhead loom over the rest of the year

The exterior of Samsung Biologics’ Plant 4. Photo=Samsung Biologics
The exterior of Samsung Biologics’ Plant 4. Photo=Samsung Biologics

With wage and collective bargaining talks between Samsung Biologics and its union still unresolved, analysts expect only a limited impact on the company’s second-quarter financial results. However, potential one-time labor costs and early-stage expenses tied to its new U.S. manufacturing facility could weigh on profitability during the second half of the year.

According to industry sources on June 30, the Samsung Bio Mutual Growth Branch union decided to withdraw from the Samsung Group cross-company union framework following a membership vote held from June 24 to 28. The measure passed overwhelmingly, with 2,392 out of 2,479 voters—or 96.5%—casting ballots in favor of the exit.

The momentum for joint bargaining across the broader Samsung Group level began to weaken after Samsung Electronics' labor and management successfully finalized their own wage agreement. Against this backdrop, the Samsung Biologics union appears to be shifting away from group-level solidarity to focus entirely on issues specific to its own standalone wage and collective bargaining negotiations.

Some industry observers suggest the withdrawal could actually improve the negotiating environment. They argue that by focusing strictly on workplace-specific issues rather than coordinating a massive groupwide response, both sides may find it easier to pinpoint areas of mutual agreement. Conversely, others note the move dilutes the leverage of group solidarity. With bargaining disputes unresolved and a series of ongoing complaints and counter-complaints still active, it remains unclear whether this tactical shift will quickly translate into a finalized deal.

Labor and management have been engaged in wage and collective bargaining talks since their inaugural meeting on December 23 of last year, failing to reach an accord for more than six months. Tensions escalated when the union staged a partial strike from April 28 to 30, followed by the company's first-ever full strike from May 1 to 5, which drew approximately 2,500 participants. Management estimates that the resulting strike disruptions caused financial losses of roughly 150 billion won.

The union's initial package demanded a 14.3% increase in base pay, a flat 3.5 million won increase, the payment of a 30 million won encouragement bonus, and an excess profit incentive (OPI) funded by 20% of operating profit. In contrast, management countered with a 6.2% wage increase, an encouragement bonus of approximately 6 million won, and an OPI funded by 10% of operating profit. Although the union subsequently submitted a revised proposal easing some of its demands, the gap between the two sides remains wide, and no breakthrough has been reported.

Despite the friction, market analysts expect the company's second-quarter earnings to remain resilient, buoyed by favorable foreign exchange rates and high utilization rates across Plants 1 through 4. Looking ahead to the second half, the operational ramp-up of Plant 5 and incoming revenue contributions from the Rockville plant in the United States are projected to serve as primary growth drivers. Reflecting this optimism, DB Financial Investment forecast second-quarter revenue of 1.3068 trillion won and an operating profit of 586.8 billion won. IBK Investment & Securities estimated revenue at 1.3189 trillion won and operating profit at 606.1 billion won, while Daol Investment & Securities projected revenue of 1.3097 trillion won and an operating profit of 590.6 billion won.

The primary concern for investors is that underlying risks have not disappeared; they are simply unlikely to manifest in the second-quarter figures. Crucially, if labor and management strike a deal in the latter half of the year, retroactive one-time labor costs could suddenly pressure margins. Analysts at Daol Investment & Securities noted that new orders experienced delays during the first half of this year, projecting that a second-half labor settlement would introduce immediate cost burdens. Additionally, while the U.S. Rockville plant began operations in the second quarter and is expected to contribute meaningfully to revenue starting in the third quarter, its initial manufacturing ramp-up will inevitably bring heavy overhead expenses.

Faced with these mixed variables, brokerage sentiment remains split. DB Financial Investment maintained its target price for Samsung Biologics at 2.2 million won, and IBK Investment & Securities kept its target steady at 2.09 million won. On the other hand, Daol Investment & Securities lowered its target price from 2.2 million won to 2.1 million won, explicitly citing delayed new orders, potential one-time labor payouts upon a union agreement, and the early operational expenses of the U.S. facility.

×